Danxin Wang1, Michael F Para, Susan L Koletar, Wolfgang Sadee. 1. Department of Pharmacology, Program in Pharmacogenomics, School of Biomedical Science, Ohio State University, Columbus, Ohio 43210, USA. wang.808@osu.edu
Abstract
OBJECTIVES: N-acetyltransferase 1 (NAT1) metabolizes drugs and environmental carcinogens. NAT1 alleles *10 and *11 have been proposed to alter protein level or enzyme activity compared with wild-type NAT1 *4 and to confer cancer risk, through uncertain pathways. This study characterizes regulatory polymorphisms and underlying mechanisms of NAT1 expression. METHODS: We measured allelic NAT1 mRNA expression and translation, as a function of multiple transcription start sites, alternative splicing, and three 3'-polyadenylation sites in human livers (one of which was discovered in this study), B lymphocytes, and transfected cells. In a clinical study of 469 patients with HIV/AIDS treated with the NAT1/NAT2 substrate sulfamethoxazole (SMX), associations were tested between SMX-induced hypersensitivity and NAT1 *10 and *11 genotypes, together with known NAT2 polymorphisms. RESULTS: NAT1 *10 and *11 were determined to act as common regulatory alleles accounting for most NAT1 expression variability, both leading to increased translation into active protein. NAT1 *11 (2.4% minor allele frequency) affected 3'-polyadenylation site usage, thereby increasing formation of NAT1 mRNA with intermediate length 3'-untranslated region (major isoform) at the expense of the short isoform, resulting in more efficient protein translation. NAT1 *10 (19% minor allele frequency) increased translation efficiency without affecting 3'-untranslated region polyadenylation site usage. Livers and B-lymphocytes with *11/*4 and *10/*10 genotypes displayed higher NAT1 immunoreactivity and NAT1 enzyme activity than the reference genotype *4/*4. Patients who carry *10/*10 and *11/*4 (fast NAT1 acetylators) were less likely to develop hypersensitivity to SMX, but this was observed only in individuals who are also carrying a slow NAT2 acetylator genotype. CONCLUSION: NAT1 *10 and *11 significantly increase NAT1 protein level/enzyme activity, enabling the classification of carriers into reference and rapid acetylators. Rapid NAT1 acetylator status seems to protect against SMX toxicity by compensating for slow NAT2 acetylator status.
OBJECTIVES:N-acetyltransferase 1 (NAT1) metabolizes drugs and environmental carcinogens. NAT1 alleles *10 and *11 have been proposed to alter protein level or enzyme activity compared with wild-type NAT1 *4 and to confer cancer risk, through uncertain pathways. This study characterizes regulatory polymorphisms and underlying mechanisms of NAT1expression. METHODS: We measured allelic NAT1 mRNA expression and translation, as a function of multiple transcription start sites, alternative splicing, and three 3'-polyadenylation sites in human livers (one of which was discovered in this study), B lymphocytes, and transfected cells. In a clinical study of 469 patients with HIV/AIDS treated with the NAT1/NAT2 substrate sulfamethoxazole (SMX), associations were tested between SMX-induced hypersensitivity and NAT1 *10 and *11 genotypes, together with known NAT2 polymorphisms. RESULTS:NAT1 *10 and *11 were determined to act as common regulatory alleles accounting for most NAT1expression variability, both leading to increased translation into active protein. NAT1 *11 (2.4% minor allele frequency) affected 3'-polyadenylation site usage, thereby increasing formation of NAT1 mRNA with intermediate length 3'-untranslated region (major isoform) at the expense of the short isoform, resulting in more efficient protein translation. NAT1 *10 (19% minor allele frequency) increased translation efficiency without affecting 3'-untranslated region polyadenylation site usage. Livers and B-lymphocytes with *11/*4 and *10/*10 genotypes displayed higher NAT1 immunoreactivity and NAT1 enzyme activity than the reference genotype *4/*4. Patients who carry *10/*10 and *11/*4 (fast NAT1acetylators) were less likely to develop hypersensitivity to SMX, but this was observed only in individuals who are also carrying a slow NAT2acetylator genotype. CONCLUSION:NAT1 *10 and *11 significantly increase NAT1 protein level/enzyme activity, enabling the classification of carriers into reference and rapid acetylators. Rapid NAT1acetylator status seems to protect against SMXtoxicity by compensating for slow NAT2acetylator status.
Authors: William M O'Neil; Rodger D MacArthur; Marti J Farrough; Mark A Doll; Adrian J Fretland; David W Hein; Lawrence R Crane; Craig K Svensson Journal: J Clin Pharmacol Date: 2002-06 Impact factor: 3.126
Authors: Danxin Wang; Xiaochun Sun; Yan Gong; Brian E Gawronski; Taimour Y Langaee; Mohamed Hossam A Shahin; Sherief I Khalifa; Julie A Johnson Journal: Drug Metab Dispos Date: 2012-01-30 Impact factor: 3.922
Authors: Todd M Gibson; Karin E Smedby; Christine F Skibola; David W Hein; Susan L Slager; Silvia de Sanjosé; Claire M Vajdic; Yawei Zhang; Brian C-H Chiu; Sophia S Wang; Henrik Hjalgrim; Alexandra Nieters; Paige M Bracci; Anne Kricker; Tongzhang Zheng; Carol Kolar; James R Cerhan; Hatef Darabi; Nikolaus Becker; Lucia Conde; Theodore R Holford; Dennis D Weisenburger; Anneclaire J De Roos; Katja Butterbach; Jacques Riby; Wendy Cozen; Yolanda Benavente; Casey Palmers; Elizabeth A Holly; Joshua N Sampson; Nathaniel Rothman; Bruce K Armstrong; Lindsay M Morton Journal: Cancer Causes Control Date: 2012-11-18 Impact factor: 2.506
Authors: Wolfgang Sadee; Katherine Hartmann; Michał Seweryn; Maciej Pietrzak; Samuel K Handelman; Grzegorz A Rempala Journal: Hum Genet Date: 2014-08-09 Impact factor: 4.132